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Human polo-like kinase 1 (PLK1) expression has been associated with inferior outcomes in co-
lorectal cancer. Our aims were to analyse PLK1 in rectal cancer, and its association with clinico-
pathological variables, overall survival as well as tumour regression to neoadjuvant treatment.
Methods
PLK1 expression was quantified with immunohistochemistry in the centre and periphery (in-
vasive front) of rectal cancers, as well as in the involved regional lymph nodes from 286 pa-
tients. Scores were based on staining intensity and percentage of positive cells, multiplied
to give weighted scores from 1–12, dichotomised into low (0–5) or high (6–12).
Results
PLK1 scores in the tumour periphery were significantly different to adjacent normal mucosa.
Survival analysis revealed that low PLK1 score in the tumour periphery had a hazard ratio
of death of 0.59 in multivariate analysis. Other predictors of survival included age, tumour
depth, metastatic status, vascular and perineural invasion and adjuvant chemotherapy.
There was no statistically significant correlation between PLK1 score and histological tu-
mour regression in the neoadjuvant cohort.
Conclusion
Low PLK1 score was an independent predictor of superior overall survival, adjusting for
multiple clinicopathological variables including treatment.
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Introduction
Colorectal cancer is one of the leading causes of mortality in the developed world. Rectal can-
cers comprise a third of these cases and carry a worse prognosis than colon cancers. In the lo-
cally advanced setting, they are treated differently to colon cancers, with trimodality therapy
consisting of neoadjuvant chemoradiation, surgery and adjuvant chemotherapy [1]. Rectosig-
moid tumours are treated akin to colonic tumours, as is metastatic rectal cancer. There is a
need for biomarkers to inform prognosis and choice of therapy, assess treatment response, and
aid in the stratification of patient risk in order to adapt and personalise patient care.
Recently, Rodel and colleagues reported polo-like kinase 1 (PLK1) to be a novel predictive
biomarker for radiation sensitivity in rectal cancer [2]. We hypothesise that over-expression of
PLK1 correlates with poorer outcomes in rectal cancer. PLK1 is a mitotic serine/threonine ki-
nase cell cycle regulator necessary for cell division, involved in the regulation of mitotic entry,
spindle formation and cytokinesis [3–5]. The functional significance of PLK1 in carcinogenesis
and malignant progression is not clearly understood, but nonetheless its overexpression is
found in many cancer types [2,6], including colorectal cancer [7,8]. Its tumourigenic capability
has been shown in nude mice injected with PLK1-overexpressing NIH3T3 fibroblasts [9]. Utili-
sation of small interfering RNA [10,11] and antisense oligonucleotides [12] in malignant cells
to deplete PLK1 levels also induced apoptosis and containment of malignant proliferation in
in-vitro and in-vivomodels. PLK1 activity is necessary in repair from DNA damage resulting
from chemo- and radiotherapy [13]. Hence PLK1 appears to be a promising predictive and
prognostic biomarker, and herein we investigate its role in rectal cancer. We also aim to show
that PLK1 is independent of the cell proliferation marker Ki67.
Materials and Methods
Ethics approval was obtained on 22nd June 2012 from the Sydney South-West Area Health Ser-
vice Ethics Review Committee, reference number HREC/12/LPOOL/102. The institutional re-
view board waived the need for written informed consent from the participants as the project
was deemed to be in the low or negligible risk category. Information was de-identified prior
to analysis.
Specimens from primary surgery for rectal or rectosigmoid cancers were obtained from the
South-Western Area Pathology database, Australia from 2000–2010. Surgery consisted of total
mesorectal excision, with anterior or abdominoperineal resection. Variables of interest includ-
ed age, gender, pathological stage of tumour, grade, vascular invasion, perineural invasion, tu-
mour-infiltrating lymphocytes and treatment. Staging was based on the American Joint
Committee on Cancer (AJCC) tumour-node-metastases (TNM) system. Outcomes of interest
were overall survival (OS) and histological tumour regression (TRG) in the resected bowel for
cases treated with neoadjuvant chemoradiation. OS was defined as the time from diagnosis to
last follow-up or death. TRG was graded based on the AJCC criteria, modified from Ryan [14]:
complete response with no viable malignant cells (0), moderate response with single or small
group of malignant cells (1), minimal response with residual malignancy outgrown by fibrosis
(2) and poor response with extensive residual malignancy (3). RG 0, 1 and 2 were categorised
as responders and TRG 3 as non-responders. Follow-up consisted of regular clinic visits, colo-
noscopy, blood tests and imaging at the discretion of the treating specialist.
For each patient, donor blocks of paraffin embedded tissue were retrieved from the anatom-
ical pathology department. Two cores, each one millimetre in diameter, were obtained from
each sampling site which included the tumour centre (TC), tumour periphery (TP), normal
mucosa close to tumour (NCT) and normal mucosa away from tumour (NAT). Two tissue
cores from lymph nodes (LN) in the node-positive cases were also obtained. TC was taken
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from centre of tumour mass, TP from the infiltrating/invasive tumour periphery, NCT from
normal mucosa immediately adjacent to tumour and NAT from normal mucosa well away
from tumour, usually at the end margins of the resected bowel. These were transferred into the
pre-drilled wells in the tissue microarray (TMA) block using the Beecher Manual tissue array-
er-1 (Sun Prairie, WI, USA). The TMA blocks were heated for 5 minutes in 60°C oven to seal
the gaps between tissue cores and surrounding paraffin.
Slide sections taken from the TMAs were deparaffinised with xylene, followed by absolute
alcohol, then re-hydrated in alcohol gradient. Antigen was retrieved in heat in 98°C water bath
with Tris EDTA (pH 9.0) buffer. Endogenous peroxidase activity was blocked with H2O2, prior
to incubation with PLK1 primary monoclonal mouse antibody (1:50 dilution, sc17783, Santa
Cruz Biotechnology). The antibody was sourced and stained as per previously published meth-
od [15]. Linker step with mouse linker solution, followed by secondary antibody incubation
(Envision polymer FLEX/HRP, Dako) preceded the application of chromogen (Flex DAB,
Dako) and counterstaining with haematoxylin. Ki67 was stained on the Dako Autostainer
using the supplied antibody at 1:100 dilution, with heat induced epitope retrieval at pH 6.0 and
10 minute primary antibody incubation time.
The immunostained sections were examined by manual counting of cells in each TMA dot,
with the observer blinded to clinical outcomes. Percentage of positive cells and staining intensi-
ty of PLK1 were scored (Fig 1). Intensity was graded as negative (0), weak (1+), moderate (2+)
or strong (3+) and percentage of positive cells graded as<5% (0), 5–25% (1), 26–50% (2), 51–
75% (3) and>75% (4). These two measures were multiplied to give weighted scores from
0–12, dichotomised into low (0–5) or high (6–12), as described by Rodel [15]. The two scores
for each duplicate sampling site were averaged, obtaining the final average weighted scores (S1
Table). For Ki67, percentage staining was scored, and the two scores for each duplicate sam-
pling site were averaged (S1 Table).
Paired t-test was used to compare PLK1 in TC and TP, Fisher’s exact test for associations be-
tween PLK1 and clinicopathologic variables, and Cox regression for OS. Only cases with complete
data on all the variable domains were included in the univariate and multivariate analyses. Signifi-
cance was set at p<0.05. Variables with a univariate p-value0.2 were included in the initial mul-
tivariate model. Non-significant variables were removed iteratively and coefficients checked to
determine whether removal of a variable resulted in a large effect change for any of the remaining
variables. This was repeated until significant variables remained. Two way interactions between
the remaining variables were checked for significance and included in the model if they were sig-
nificant. The supremum test for proportional hazards assumption was used to determine whether
the hazard functions over time were constant. For variables that did not satisfy the proportional
hazards assumption, an interaction term between time and that variable was included into the
model to account for non-proportionality. Subgroup analyses were performed using a similar pro-
cedure for patients in the lymph node positive group to determine if PLK1 in the involved node
correlated with node number (Fisher’s exact test) and with survival (Cox regression). Another
subgroup analysis (Fisher’s exact test) was performed for patients who had undergone neoadju-
vant therapy to determine if there was a correlation between PLK1 and TRG. Ki67 was correlated
with PLK1 scores using logistic regression. Data analysis was generated using SAS Enterprise
Guide software, Version 6.1 of the SAS System for Windows (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of the study population
Two hundred and eighty-six cases were identified, with a median age of 73 years (S1 Table).
The cohort consisted of 34% female, 66% male, 33% pT1/2, 67% pT3/4, 48% node-positive and
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7% with metastatic disease. Median follow-up was 3.1 years and 5-year OS 58%. Twenty-two
percent received neoadjuvant therapy and 30% adjuvant therapy. Adjuvant chemotherapy con-
sisted of infusional 5-FU, capecitabine or FOLFOX (5-FU and oxaliplatin). Out of the neoadju-
vant therapy group, 25% received short-course (25 Gy in 5 fractions, 5 Gy per fraction, over 5
days) and 75% long-course concurrent chemoradiation (45 to 50.4 Gy, 1.8 Gy per fraction,
over 5 to 6 weeks, with concurrent infusional 5-fluorouracil 225mg/m2/day).
PLK1 scores
Mean weighted PLK1 score was 2.5 for tumour centre (TC) and 3.4 for tumour periphery (TP).
The breakdown of TC and TP weighted scores is shown in Table 1 and the discrete scores
shown in S1 Table. The dichotomised scores of positive versus negative are also shown. TC and
TP weighted scores were significantly different (paired t-test p<0.001). Staining in TP and TC
Fig 1. Polo-like kinase 1 immunohistochemical staining in rectal cancer cells in tissuemicroarrays in low power (a) and high power. High power
images show scores of (b) weighted score of 0, (c) weighted score of 3, from 1 (percentage 5–25%) x 3 (strong intensity) and (d) weighted score of 4
(percentage >75%) x 3 (strong intensity), note the contrast with adjacent normal glands
doi:10.1371/journal.pone.0129313.g001
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had similar proportions of>75% staining (i.e. 35%) however the proportions of 3+ staining
was 14% in TC and 25% in TP. Mean PLK1 score was 3.4 for NCT and 3.0 for NAT, and
these scores were significantly different (p = 0.025). NAT was significantly different to TP
(p = 0.011) but not to TC (0.08), hence TP was deemed to be a more accurate representation of
tumour staining, and will be used herein for analyses. The distribution of the TP scores is illus-
trated in Fig 2.
Associations between PLK1 scores and clinicopathological
characteristics
An association was found between TP scores and metastatic status, in that patients with meta-
static disease had a low TP PLK1 score in 95% of the cases compared to 72% in the non-meta-
static disease group (Table 2). There were no other significant associations.
Table 1. Polo-like kinase 1 scores (immunohistochemistry) in rectal tumour centre and periphery.
Tumour centre Tumour periphery
Weighted score Dichotomised score Weighted score Dichotomised score
0–5 243 (85%) Negative 117 (42%) 0–5 212 (74%) Negative 91 (32%)
6–12 37 (13%) Positive 163 (56%) 6–12 69 (24%) Positive 190 (66%)
Missing 6 (2%) Missing 6 (2%) Missing 5 (2%) Missing 5 (2%)
Total 286 (100%) Total 286 (100%) Total 286 (100%) Total 286 (100%)
doi:10.1371/journal.pone.0129313.t001
Fig 2. Histogram showing the distribution of the discrete tumour periphery (TP) PLK1 scores.
doi:10.1371/journal.pone.0129313.g002
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Survival analyses
The 12 variables of interest included TP PLK1 weighted score, age, gender, TNM stage, histo-
logical grade, vascular invasion, perineural invasion, presence of tumour-infiltrating lympho-
cytes, adjuvant chemotherapy and neoadjuvant treatment. There were 219 cases with complete
data on all these domains. Cox regression univariate analyses showed higher TP PLK1 score,
higher age, higher tumour T stage, metastatic status, presence of vascular and perineural inva-
sion and absence of adjuvant chemotherapy to be significant predictors of worse OS (Table 3,
Fig 3). The final multivariate model includes TP PLK1 score, nodal status, metastatic status, an
interaction between adjuvant chemotherapy and vascular status, and an interaction between
adjuvant chemotherapy and time (Table 3). High TP PLK1 score, positive nodal status, and
presence of metastasis were found to be associated with worse survival. Patients who had
not received adjuvant chemotherapy had worse survival than patients who had received
Table 2. Fisher’s test of association between tumour periphery (TP) polo-like kinase 1 (PLK1) scores and clinicopathological variables.
Variable Number Low TP PLK1 score (0–5) High TP PLK1 score (6–12) p-value
Gender 0.363
Male 186 76% 24%
Female 95 74% 26%
Age 0.527
Less than median 139 76% 25%
More than median 141 75% 25%
Tumour stage 0.478
T1 and T2 91 75% 25%
T3 and T4 190 76% 24%
Nodal stage 0.461
Negative 146 76% 24%
Positive 135 75% 25%
Metastatic status 0.021
Absent 234 72% 28%
Present 19 95% 5%
Neoadjuvant therapy 0.242
No 206 73% 27%
Yes 53 79% 21%
Grade 0.378
1 and 2 260 75% 25%
3 21 81% 19%
Vascular invasion 0.520
Absent 213 76% 24%
Present 68 75% 25%
Perineural invasion 0.534
Absent 233 76% 25%
Present 48 75% 25%
Adjuvant treatment 0.318
No 163 76% 24%
Yes 72 72% 28%
Tumour-infiltrating lymphocytes 0.256
Absent 257 77% 23%
Present 22 68% 32%
doi:10.1371/journal.pone.0129313.t002
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adjuvant chemotherapy and this effect was observed to be worse for patients whose cancers
had vascular invasion. Over time, the effect of not having adjuvant chemotherapy reduced, and
Table 3. Univariate analyses andmultivariate model of tumour periphery (TP) polo-like kinase 1 (PLK1) scores with clinicopathological variables
for survival outcomes.
Univariate Multivariate
Variable Hazard Ratio CI p-value Coefficient Hazard Ratio CI p-value
TP PLK1
Less than 6 0.72 (0.46, 1.12) 0.1452 -0.52 0.59 (0.38, 0.94) 0.0245
6 or more Reference
Gender
Male 0.96 (0.62, 1.49) 0.8649
Female Reference
Age
Less than median 0.57 (0.37, 0.88) 0.0121
More than median Reference
Tumour Stage
T1 and T2 0.59 (0.38, 0.94) 0.0249
T3 and T4 Reference
Nodal Status
Negative 0.69 (0.45, 1.04) 0.0773 -0.57 0.57 (0.36, 0.9) 0.0167
Positive Reference
Metastatic Status
Absent 0.16 (0.07, 0.33) <0.0001 -1.22 0.29 (0.12, 0.7) 0.0054
Present Reference
Neoadjuvant treatment
No 1.07 (0.62, 1.88) 0.8034
Yes Reference
Adjuvant Chemotherapy
No 2.05 (1.22, 3.43) 0.0068 3.69 <0.0001
Yes Reference
Grade
1 and 2 0.54 (0.26, 1.11) 0.0939
3 Reference
Vascular Invasion
Absent 0.49 (0.31, 0.76) 0.0015 0.82 0.2479
Present Reference
Perineural Invasion
Absent 0.46 (0.28, 0.75) 0.0016
Present Reference
TIL
Absent 2.33 (0.94, 5.75) 0.0674
Present Reference
Adjuvant chemotherapy *Vascular Invasion
No Adjuvant chemotherapy, No Vascular invasion -2.36 0.0001
Adjuvant Chemotherapy *Time -0.21 0.023
Abbreviations: CI = confidence intervals, PLK1 = polo-like kinase 1, TIL = tumour-infiltrating lymphocytes, TP = tumour periphery
* denotes interaction
doi:10.1371/journal.pone.0129313.t003
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was non-significant after 2 years for cancers without vascular invasion. However, survival re-
mained significantly worse for up to 10 years in cancers with vascular invasion (S1 Fig).
Lymph node positive subgroup
Mean LN PLK1 score in the 105 node-positive cases was 3.1. There was no statistically signifi-
cant association between LN PLK1 scores and number of nodes involved (p = 0.097). However
there appeared to be a trend between higher LN PLK1 scores and greater number of positive
nodes, with 68% of high PLK1 scores having N2 compared to N1 status. There were borderline
associations between LN PLK1 scores and vascular invasion (p = 0.064), perineural invasion
(p = 0.070) and histological grade (p = 0.057).
In univariate analyses (n = 78), LN PLK1 was not significantly associated with survival
(p = 0.114). In multivariate analyses (n = 78), LN PLK1 was not significantly associated with
survival (p = 0.7083) after adjusting for adjuvant chemotherapy and vascular invasion interac-
tion; as well as adjuvant chemotherapy and time interaction.
Neoadjuvant subgroup
Out of the 57 patients who underwent neoadjuvant chemoradiation. Twenty-three percent had
TRG grades 1 to 2 (responders) and 77% had TRG3 (non-responders). There was no signifi-
cant association between TP PLK1 score and TRG (p = 0.096).
Association between PLK1 and Ki67
Ki67 mean scores in TC, TP and LN were 9%, 8% and 4% respectively. cores in NAT and NCT
were<1%. Logistic regression revealed no significant associations between PLK1 and Ki67 in
TC (p = 0.539), TP (p = 0.406) and LN (p = 0.413).
Fig 3. Kaplan Meier survival curve for tumour peripheral (TP) polo-like kinase 1 (PLK1) weighted
scores.
doi:10.1371/journal.pone.0129313.g003
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Discussion
While there are a number of publications regarding prognostic effects of PLK1 in various
human malignancies [6,16], this is the first report to our knowledge, investigating PLK1 ex-
pression in different sampling sites from the same tumour, and demonstrating that upregulated
PLK1 expression in the periphery of the primary tumour correlates with inferior survival out-
come in rectal cancer, and is independent of proliferative marker Ki67.
We found variable expression of PLK1 in the centre and periphery of the primary tumour,
and in nodal deposits. Compared to normal mucosa away from the tumour, the peripheral
PLK1 score was significantly higher. The peripheral invasive front would be rationalised as
being more reflective of tumour behaviour as it is more biologically active with regard to inter-
action with and destruction of the surrounding tissues. The periphery of tumour mass is better
oxygenated and expected to be more responsive to radiation as opposed to the centre which
may be ischaemic or necrotic. We propose that the tumour periphery be used as the sampling
site for rectal tumour PLK1 scoring.
We demonstrated that TP weighted PLK1 score correlated with overall survival, with a HR
of 0.59. The 5-year OS was 60% in the group with low PLK1 scores compared to 50% in the
group with high PLK1 scores. Significant variables for survival included age, tumour stage,
metastatic status and interactions between adjuvant chemotherapy with vascular invasion, and
with adjuvant chemotherapy and time. TP PLK1 score was an independent prognostic factor
of survival, even after adjusting for these variables. Importantly, we have adjusted for adjuvant
treatment. Our median follow-up was 3.1 years, which would be a reflection of longer term sur-
vival given that three-year follow up is an appropriate endpoint with a high correlation with
overall survival in colorectal cancer [17].
PLK1 expression has also been documented in precursor/early cancers of other organs, such
as in ovarian cystadenoma [18] and in early papillary thyroid carcinoma [19] and previously
PLK1 over-expressing colorectal cancers have been reported to display a more radioresistant
phenotype [2]. We could not confirm this in our findings, however we recognise that the
neoadjuvant cohort comprised only a small subset of our study population and hence may
have insufficient power to demonstrate this relationship.
We also investigated PLK1 in lymph nodes in the node-positive population. There appeared
to be a trend toward an association between higher LN PLK1 score and higher node number,
which is consistent with our hypothesis that over-expression of PLK1 correlates with poorer
outcomes. However LN PLK1 did not correlate significantly with survival, within the limita-
tions of small subgroup analyses.
Low PLK1 score was significantly associated with presence of metastatic disease. Given that
our cohort consisted of a small percentage of metastatic cases (7%), the clinical utility of PLK1
will need to be explored further in this patient population. It may be hypothesized that the ma-
jority of metastatic cases did not allow for the collection of resected tissue, hence limiting the
ability to detect cases with high PLK1 staining. Larger studies are needed to define the interac-
tion between PLK1 score and metastatic status with regard to outcomes.
We also performed corroborative staining with Ki67, and demonstrated no significant asso-
ciation between PLK1 and Ki67 staining. Hence PLK1, though important in cell cycle regula-
tion, is not simply a surrogate for cell proliferation.
Our findings are consistent with observations from cell line studies, where re-instatement of
PLK1 activity is essential in recovery from G2/M checkpoint arrest following DNA damage.
The latter inhibits PLK1 which normally requires phosphorylation in its activation loop threo-
nine 210 by Bora in collation with upstream kinase. Threonine 210 phosphorylation of PLK1
peaks with the normal accumulation of Bora in G2 phase. PLK1 subsequently activates
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downstream targets and cells progress through mitosis [20]. Continued PLK1 inactivation re-
sults in delayed entry to mitosis. By contrast, overexpression of constitutively phosphorylated
PLK1 overrules the DNA damage induced G2/M checkpoint arrest [2,21,22]. This is important
in rectal cancer as radiation induces double-stranded DNA breaks. Chemotherapy agents used
in rectal cancer, either concurrent with radiation or in the adjuvant setting, include 5-fluoro-
pyrimidine which is an anti-metabolite, and oxaliplatin which is an alkylating agent that causes
cross-links in DNA.
Current therapeutic management of rectal cancer can be improved by the availability of bet-
ter predictive and prognostic biomarkers. Carcinoembryonic antigen (CEA) is currently the
only biomarker in the National Comprehensive Cancer Network (NCCN) guidelines, as part
of baseline staging and in post treatment surveillance. In the metastatic setting, K-ras is a pre-
dictive marker for response to EGFR inhibitor therapy [23]. Our results suggest that PLK1 is a
potentially useful prognostic biomarker in rectal cancer patients. PLK1 inhibition is currently
considered a promising anticancer therapeutic agent. The PLK1 inhibitor Volasertib (BI6727)
has completed phase II clinical trial to determine its anti-malignant and safety profiles [24,25].
Other PLK1 inhibitors in development include BI2536 (Axon), which if delivered before or
after radiation exposure, could respectively result in either increased cell death during mitotic
arrest or increased cell recovery following DNA repair during G2 checkpoint arrest [13]. Fur-
ther prospective studies validating the clinical utility of PLK1, as demonstrated here, in rectal
cancer management is needed to reinforce our findings and translate them into clinical use.
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